The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.
May 14th 2024
In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Amivantamab Plus Chemotherapy Nearly Doubles PFS in EGFR Exon 20–Mutant NSCLC
October 21st 2023The combination of amivantamab-vmjw (Rybrevant) and chemotherapy produced a median progression-free survival of 11.4 months vs 6.7 months with chemotherapy alone in patients with advanced, EGFR exon 20 insertion–positive non–small cell lung cancer.
Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC
October 21st 2023Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.
Selpercatinib Significantly Improves PFS Vs Chemo With or Without Pembrolizumab in RET+ NSCLC
Selpercatinib (Retevmo) showcased superior efficacy, with improved progression-free survival, vs chemotherapy with or without pembrolizumab in the first-line treatment of patients with RET fusion–positive non–small cell lung cancer.
Second-Line Sacituzumab Govitecan Elicits Responses, Provides Disease Control in ES-SCLC
Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.
Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC
Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.
Pembrolizumab Plus Adagrasib Demonstrates Preliminary Efficacy in KRAS G12C–Mutated NSCLC
October 20th 2023Concurrent adagrasib and pembrolizumab generated early signals of efficacy in patients with treatment-naïve, advanced non–small cell lung cancer harboring KRAS G12C mutations, particularly in those who had a PD-L1 tumor proportion score of at least 50%.
ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types
The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.
Novel KRAS G12C Inhibitor Reflects Research Advances in NSCLC and CRC
October 19th 2023David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.
FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC
The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment for patients with resectable non–small cell lung cancer.
Dendritic Cell Vaccination Fails to Improve OS, Still Bolsters Immune Activation in Mesothelioma
October 16th 2023Joachim G. J. V. Aerts, MD, PhD, discusses how dendritic cell vaccines could bolster historically poor responses to immunotherapy in patients with mesothelioma, reports and provides potential explanations for negative results from the DENIM trial, and details a potential role for this therapy in earlier lines of mesothelioma treatment.
European Commission Approves Adjuvant Pembrolizumab for High-Risk NSCLC
October 16th 2023The European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.
FDA Approves Companion Diagnostics for Encorafenib/Binimetinib in BRAF V600E+ Metastatic NSCLC
The FDA has approved FoundationOne® CDx and FoundationOne Liquid CDx for use as companion diagnostics to identify patients with metastatic non–small cell lung cancer harboring BRAF V600E mutations who may benefit from treatment with the combination of encorafenib plus binimetinib.
Dr Salgia on Unmet Needs Associated With Treatment-Related Toxicity in Lung Cancer
October 12th 2023Ravi Salgia, MD, PhD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting unmet needs that remain regarding treatment-related toxicities that can arise with commonly used agents in patients with lung cancer.